Search

Pietro Maffei, Silvia Bettini, Luca Busetto, Francesca Dassie Department of Medicine, Padua University, Padua, ItalyCorrespondence: Pietro Maffei, Email pietro.maffei@unipd.itAbstract: SGLT2i (sodium glucose transporter type 2 inhibitors) are pharmacological agents that act by inhibiting the SGLT2, by reducing the renal plasma glucose threshold and inducing glycosuria, resulting in a blood glucose lowering effect. In recent years, studies demonstrating some additional positive effects of SGLT2i also in the treatment of T1D have increased progressively. The SGLT2i dapagliflozin and sotagliflozin have been temporarily licensed for use by the European Medical Agency (EMA) as an adjunct to insulin therapy in adults with T1D with a body mass index of 27 kg/m2 or higher. However, in the meantime, the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee was divided, citing concerns about the main side effects of SGLT2i, especially diabetic ketoacidosis (DKA). The aim of this manuscript was to conduct an update on current evidence and recommendations of the reported use of SGLT2i in the treatment of T1D in humans. Preclinical studies, clinical trial and real world data suggest benefits in glycaemia control and nefro-cardiovascular protection, even though several studies have documented an important increase in the risk of DKA, a serious and life-threatening adverse event of these agents. SGLT2i potentially addresses some of the unmet needs associated with T1D by improving glycaemic control with weight loss and without increasing hypoglycemia, by reducing glycaemic variability. However, due to side effects, EMA recommendation for SGLT2 use on T1D was withdrawn. Further studies will be needed to determine the safety of this therapy in T1D and to define the type of patient who can benefit most from these medications.Keywords: dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, mechanism, clinical studies

The feasibility to obtain highly porous collagen-based scaffolds (SCs) integrated with uniformly dispersed poly(lactide-co-glycolide) (PLGA) microparticles (MPs) was evaluated. PLGA-MPs were prepared by double emulsion technique and SCs with different amounts of MPs (SC/PLGA-MPs) were produced. Results showed that SC/PLGA-MPs could be successfully manufactured, the PLGA-MPs being physically retained in the SCs, without affecting the porous structure. PLGA-MPs also increased the SC hydrophilicity, acted as a mechanical reinforcement and retarded the degradation rate. In addition, the interactions between MPs and Caco-2 cells did not interfere with the correct morphological, adhesion and proliferation pathways. [ABSTRACT FROM AUTHOR]

Superparamagnetic magnetite nanoparticles were synthetized and capped by a SiO2 shell in order to avoid oxidation and aggregation of the iron oxide nanostructures. The inorganic capping was then further decorated by folic acid molecules, by using a very simple procedure exploiting supramolecular interactions among the organic moieties and the inorganic nanoparticles. The supramolecular nanoadduct thanks to folic acid molecules could act as a “Trojan horse” for the cancer cells and due to its superparamagnetic properties could induce local heat generation upon an appropriate magnetic field application. In fact, temperature was increased up to 42 °C when a 18 mT magnetic field was applied to the nanoparticles and the hybrid nanostructures were verified to be selectively internalized by HeLa cells, a human cervical cancer line known to overexpress the folic acid receptor. [ABSTRACT FROM AUTHOR]